As a patent agent and technical advisor, Hervé Jacquiau, Ph.D., assists in all aspects of the firm’s patent practice, including patent prosecution and litigation. His background covers a variety of technologies, particularly biotechnology, bioengineering, biochemistry, molecular biology and microbiology.
Hervé received his Ph.D. from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants. He developed novel genetic tools to identify the specific nature of chromosomal DNA mutations and became co-inventor on a U.S. patent. His work contributed to the creation of a biotechnology company that specializes in developing biosensors for the detection and removal of environmental contaminants.
As a postdoctoral research associate, Hervé investigated various mechanisms that regulate cellular sensitivity or resistance to anti-cancer agents. He investigated DNA rearrangements and cell-cycle regulation and highlighted the role of various mechanisms of protein degradation in modulating cellular response to enzyme inhibitors that are commonly used in the treatment of childhood cancer.
Hervé previously worked at the Lankenau Institute for Medical Research, where he first developed antibodies to be used in cancer diagnostics or research tools to validate biomarkers of breast and ovarian cancer. At the institute, Hervé evaluated scientific innovations and business proposals and subsequently became a business and scientific funding associate in the Department of Business Development.
He contributed to the creation of a novel drug screening facility for drug target validation and drug discovery, as well as a center for the production of human antibodies to be used as medical diagnostics or as novel therapeutics. He collaborated with surgeons and clinicians to develop protocols for clinical trials. Hervé also wrote proposals to attract funding and to promote scientific collaborations.
Earlier in his career, Hervé earned a master of science degree in bioreactor systems after studying genetics, bioengineering, biotechnology, fermentation optimization and kinetics, as well as upstream and downstream processes. As an undergraduate, he studied biological sciences, as well as the food and biological industries.
- Patent Agent & Technical Advisor, Hahn Loeser & Parks LLP, 2015-present
- Technical Advisor & Patent Agent, Husch Blackwell LLP, 2009-15
- Research Grant Writer & Business and Scientific Funding Associate, Lankenau Institute for Medical Research, Department of Business Development, 2008-09
- Junior Faculty Member: Scientist, Lankenau Institute for Medical Research, 2006-07
- Postdoctoral Research Associate, St. Jude Children’s Research Hospital, Department of Molecular Pharmacology, 2000-06
- Patents – Biosensor Materials and Methods (co-inventor), United States Patent Approved (US 6,849,442 B1), Feb. 1, 2005
University of Cambridge (UK), Ph.D., Genetics, 2000
Honors & Activities: Marie Curie Research Fellowship, Recipient; Industrial Case Studentship, Biotechnology & Biological Sciences Research Council, Recipient
University of Manchester Institute of Science and Technology, M.S., Bioreactor Systems, 1995.
Honors & Activities: Goodwill Ambassadorial Scholarship of the Rotary International, Recipient
Manchester Metropolitan University, B.S., Applied Biology, 1994
Paris XII University, University Institute of Technology, D.U.T., Food and Biological Industries, 1992
American Association for Cancer Research, Member
American Intellectual Property Law Association, Member
The American Society for Microbiology, Member
The Genetics Society of America, Member
Intellectual Property Law Association of Chicago, Member
Marie Curie European Research Fellowship Association, Member
Phi Alpha Delta Law Fraternity, Member
University of Cambridge Alumni Association, Member
University of Manchester/UMIST Alumni Association, Member
U.S. Patent and Trademark Office (Registration Number: 64976)
Co-Inventor, Biosensor Materials and Methods, United States Patent Approved (US 6,849,442 B1), Feb. 1, 2005